Viatris Inc. (VTRS)
VTRS Stock Price Chart
Explore Viatris Inc. interactive price chart. Choose custom timeframes to analyze VTRS price movements and trends.
VTRS Company Profile
Discover essential business fundamentals and corporate details for Viatris Inc. (VTRS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
17 Mar 1980
Employees
32.00K
Website
https://www.viatris.comCEO
Scott Andrew Smith
Description
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
VTRS Financial Timeline
Browse a chronological timeline of Viatris Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is $0.63, while revenue estimate is $3.60B.
Earnings released on 7 Aug 2025
EPS came in at $0.62 surpassing the estimated $0.56 by +11.51%, while revenue for the quarter reached $3.58B , beating expectations by +3.32%.
Dividend declared on 4 Aug 2025
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend will be paid on 15 Sept 2025.
Earnings released on 8 May 2025
EPS came in at $0.50 surpassing the estimated $0.49 by +1.65%, while revenue for the quarter reached $3.25B , beating expectations by +0.59%.
Dividend declared on 5 May 2025
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 16 Jun 2025.
Earnings released on 27 Feb 2025
EPS came in at $0.54 falling short of the estimated $0.61 by -11.48%, while revenue for the quarter reached $3.53B , missing expectations by -2.00%.
Dividend declared on 27 Feb 2025
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 18 Mar 2025.
Earnings released on 7 Nov 2024
EPS came in at $0.75 surpassing the estimated $0.68 by +10.78%, while revenue for the quarter reached $3.74B , beating expectations by +0.61%.
Dividend declared on 4 Nov 2024
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 13 Dec 2024.
Earnings released on 8 Aug 2024
EPS came in at $0.69 surpassing the estimated $0.68 by +1.77%, while revenue for the quarter reached $3.80B , beating expectations by +0.42%.
Dividend declared on 5 Aug 2024
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 13 Sept 2024.
Earnings released on 9 May 2024
EPS came in at $0.67 falling short of the estimated $0.67 by -0.45%, while revenue for the quarter reached $3.66B , missing expectations by -0.75%.
Dividend declared on 6 May 2024
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 14 Jun 2024.
Earnings released on 28 Feb 2024
EPS came in at $0.61 falling short of the estimated $0.67 by -8.96%, while revenue for the quarter reached $3.84B , missing expectations by -0.84%.
Dividend declared on 26 Feb 2024
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 18 Mar 2024.
Earnings released on 7 Nov 2023
EPS came in at $0.78 surpassing the estimated $0.74 by +5.41%, while revenue for the quarter reached $3.94B , beating expectations by +1.94%.
Dividend declared on 7 Nov 2023
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 15 Dec 2023.
Earnings released on 7 Aug 2023
EPS came in at $0.75 surpassing the estimated $0.71 by +5.63%, while revenue for the quarter reached $3.92B , beating expectations by +1.37%.
Dividend declared on 4 Aug 2023
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 15 Sept 2023.
Earnings released on 8 May 2023
EPS came in at $0.78 surpassing the estimated $0.69 by +13.04%, while revenue for the quarter reached $3.73B , missing expectations by -2.07%.
Dividend declared on 5 May 2023
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 16 Jun 2023.
Earnings released on 27 Feb 2023
EPS came in at $0.67 falling short of the estimated $0.72 by -6.94%, while revenue for the quarter reached $3.88B , missing expectations by -2.87%.
Dividend declared on 24 Feb 2023
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 17 Mar 2023.
Earnings released on 7 Nov 2022
EPS came in at $0.86 surpassing the estimated $0.82 by +4.88%, while revenue for the quarter reached $4.08B , missing expectations by -1.39%.
Dividend declared on 7 Nov 2022
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 16 Dec 2022.
Earnings released on 8 Aug 2022
EPS came in at $0.88 surpassing the estimated $0.81 by +8.64%, while revenue for the quarter reached $4.12B , missing expectations by -1.63%.
Dividend declared on 4 Aug 2022
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 16 Sept 2022.
Earnings released on 9 May 2022
EPS came in at $0.93 surpassing the estimated $0.81 by +14.81%, while revenue for the quarter reached $4.19B , missing expectations by -0.95%.
Dividend declared on 5 May 2022
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 16 Jun 2022.
Earnings released on 28 Feb 2022
EPS came in at $0.80 falling short of the estimated $0.82 by -2.44%, while revenue for the quarter reached $4.34B , missing expectations by -0.10%.
Dividend declared on 6 Jan 2022
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 16 Mar 2022.
Earnings released on 8 Nov 2021
EPS came in at $0.99 surpassing the estimated $0.86 by +15.12%, while revenue for the quarter reached $4.54B , beating expectations by +3.31%.
Dividend declared on 8 Nov 2021
A dividend of $0.11 per share was announced, adjusted to $0.11. The dividend was paid on 16 Dec 2021.
Earnings released on 9 Aug 2021
EPS came in at $0.98 surpassing the estimated $0.88 by +11.36%, while revenue for the quarter reached $4.58B , beating expectations by +4.55%.
Dividend declared on 9 Aug 2021
A dividend of $0.11 per share was announced, adjusted to $0.11. The dividend was paid on 16 Sept 2021.
Earnings released on 10 May 2021
EPS came in at $0.92 surpassing the estimated $0.79 by +16.46%, while revenue for the quarter reached $4.43B , beating expectations by +17.65%.
Dividend declared on 10 May 2021
A dividend of $0.11 per share was announced, adjusted to $0.11. The dividend was paid on 16 Jun 2021.
Earnings released on 1 Mar 2021
EPS came in at $0.94 falling short of the estimated $1.24 by -24.19%, while revenue for the quarter reached $3.62B .
Earnings released on 6 Nov 2020
EPS came in at $1.31 surpassing the estimated $1.16 by +12.93%, while revenue for the quarter reached $2.97B , beating expectations by +13.59%.
VTRS Stock Performance
Access detailed VTRS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.